Host AMPK Is a Modulator of Plasmodium Liver Infection  by Ruivo, Margarida T. Grilo et al.
ReportHost AMPK Is a Modulator of Plasmodium Liver
InfectionGraphical AbstractHighlightsd Plasmodium-infected hepatic cells exhibit decreased AMPK
activity
d AMPK suppression favors hepatic infection; its activation
reduces parasite development
d AMPK activating compounds efficiently reduce liver infection
in vitro and in vivoRuivo et al., 2016, Cell Reports 16, 2539–2545
September 6, 2016 ª 2016 The Authors.
http://dx.doi.org/10.1016/j.celrep.2016.08.001Authors
Margarida T. Grilo Ruivo,
Iset Medina Vera, Joana Sales-Dias, ...,







AMPK is a stress-activated kinase that
regulates cellular energy homeostasis.
Ruivo et al. show that AMPK signaling is
relevant to hepatocyte infection by
malaria parasites. Induction of host
AMPK activity affects the ability of the
host cell to support parasite growth in the
liver, thus reducing the subsequent
malaria burden.
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Manipulation of the master regulator of energy ho-
meostasis AMP-activated protein kinase (AMPK)
activity is a strategy used by many intracellular path-
ogens for successful replication. Infection by most
pathogens leads to an activation of host AMPK activ-
ity due to the energetic demands placed on the in-
fected cell. Here, we demonstrate that the opposite
is observed in cells infected with rodent malaria par-
asites. Indeed, AMPK activity upon the infection of
hepatic cells is suppressed and dispensable for suc-
cessful infection. By contrast, an overactive AMPK is
deleterious to intracellular growth and replication of
different Plasmodium spp., including the human
malaria parasite, P. falciparum. The negative impact
of host AMPK activity on infection was further
confirmed in mice under conditions that activate its
function. Overall, this work establishes the role of
host AMPK signaling as a suppressive pathway of
Plasmodium hepatic infection and as a potential
target for host-based antimalarial interventions.INTRODUCTION
Plasmodium spp. are obligate intracellular protozoan parasites
and the etiological agents of malaria, an infectious disease that
causes major morbidity and mortality and cripples socioeco-
nomic growth. Lack of an effective vaccine and resistance to
treatments are setbacks for controlling the disease (World Health
Organization, 2015). Malaria infection begins in the liver, when
the transmissive forms (sporozoites) invade and replicate by
schizogony into thousands of new parasites (merozoites) inside
hepatocytes. This high replicative capacity occurs within 48 hr
in rodent parasites and up to 2 weeks in human parasites.
Despite clear parasitism and subversion of host cell resources
during hepatic infection, little is known about how Plasmodium
infection modifies hepatocyte signaling. Previous transcriptional
and post-transcriptional studies provide evidence of parasite-Cell Rep
This is an open access article undmediated alterations to host cell processes (Albuquerque et al.,
2009; Kaushansky et al., 2013). Nonetheless, a comprehensive
understanding of the hepatocyte response to this first stage of
Plasmodium infection is needed to devise new antimalarial
interventions.
Many intracellular pathogens actively alter host cellular meta-
bolism as a strategy to produce optimal conditions for prolifer-
ation. An obvious metabolic target is AMPK (AMP-activated
protein kinase), the master regulator of cellular energy homeo-
stasis. AMPK is a conserved heterotrimeric (a catalytic, b and
g regulatory subunits) serine/threonine kinase that, as its name
implies, responds to an increased AMP/ATP ratio. AMPK
activation influences diverse pathways from glucose and lipid
metabolism to cell-cycle regulation, promoting catabolism
and inhibiting ATP consuming processes (reviewed in Hardie,
2014).
Manipulation of host AMPK activity is described for virus, bac-
teria, and parasite infections. For example, Mycobacterium,
Leishmania, human cytomegalovirus, vaccinia, and simian va-
cuolating virus 40 induce AMPK activity, while hepatitis C virus
(HCV) suppresses AMPK activity (Moreira et al., 2015; Singhal
et al., 2014; reviewed in Brunton et al., 2013). Thus, AMPK mod-
ulation varies with the pathogen and the host cellular context and
is dependent on the specific energetic requirements.
In this study, we investigated the role of host AMPK during
the course of Plasmodium hepatic infection. We show that
host AMPK function is suppressed during infection by these
parasites. Using several in vitro and in vivo approaches,
we demonstrate that activation of the AMPK signaling path-
way impairs the intracellular replication of malaria liver-stage
parasites.RESULTS
Plasmodium Hepatic Infection Leads to Decreased
AMPK Function
AMPK activity can be determined by the phosphorylation of a
threonine (T172) residue in the AMPKa catalytic subunit as well
as the phosphorylation of the main downstream effector
acetyl-coA (coenzyme A) carboxylase (ACC, S79), a rate-limiting
enzyme in fatty acid synthesis (Hardie and Pan, 2002). To testorts 16, 2539–2545, September 6, 2016 ª 2016 The Authors. 2539
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
A B C Figure 1. P. bergheiHepatic Infection Alters
the AMPK Activation Status
(A) Timeline of infection and sample collection.
Huh7 cells were infected with GFP-expressing
P. berghei sporozoites (spz) and subjected to
fluorescence-activated cell sorting to separate
infected from non-infected (ni) cells at 2 hr post-
infection. Cells were re-plated 1:1 (infected:non-
infected), cultured for 16 hr, and compared to non-
infected by western blot (WB).
(B and C) WB analysis of lysates from non-infected
(ni) and enriched infected (inf) Huh7 cells collected
at 18 hr post-infection, probing with anti-phospho-
AMPKa (pAMPKaT172), -phospho-ACC (pACCS79),
and -actin antibodies. (B) Representative blot and
(C) quantitative analysis (mean ± SEM) of three in-
dependent experiments. Analysisof additional time
points and control (ctrl) for total AMPKa abundance
is shown in Figure S1. **p < 0.01; ***p < 0.001.whether AMPK activation is altered upon Plasmodium infection,
we compared the phosphorylation status of AMPKa and ACC in
non-infected Huh7 cells versus cells infected with the rodent
parasite P. berghei (Figure 1A). Phosphorylation of AMPKa and
ACC is lower in infected cells when compared to the non-in-
fected cells at 18 hr post-infection (p < 0.01; Figures 1B and
1C). We confirmed a decrease in AMPKa phosphorylation over
time (Figure S1A) and verified that total AMPKa abundance is
not altered during infection (Figure S1B). A general reduction in
phosphorylation was ruled out, since we observed a modest in-
crease in phospho-Akt levels, as previously reported (data not
shown; Kaushansky et al., 2013).
Modulation of Host AMPK Affects P. berghei Hepatic
Development In Vitro
Next, we investigated whether AMPK function could impact
P. berghei infection. AMPKa catalytic subunit is encoded by
two distinct genes, prkaa1 (AMPKa1) and prkaa2 (AMPKa2),
which are expressed in hepatocytes. We knocked down both
subunits by RNAi 48 hr prior to infection and confirmed a
decrease in AMPKa and ACC phosphorylation at the time
of infection (Figures 2A and 2B). Microscopic analysis of
P. berghei-infected Huh7 cells at 48 hr post-infection revealed
a small, but significant, increase in mean size distribution of
schizont parasite forms (194 ± 127 mm2 versus 150.9 ±
99 mm2, p < 0.0001; Figure 2C). We confirmed this difference
in parasite size by testing infection in mouse embryonic fibro-
blasts (MEFs) lacking both catalytic subunits (Laderoute et al.,
2006) (291.2 ± 175 mm2 versus 176.8 ± 116 mm2, p < 0.0001;
Figure 2D).
To testwhetherAMPK functionmight hinder infection,weover-
expressed a constitutively active (CA) form of AMPKa1 subunit
(Crute et al., 1998) in Huh7 cells. As controls, we expressed an
inactive mutant AMPKa1 variant (T172A) and an empty plasmid
(Figures 2E and S2A). AMPKa and ACC phosphorylation status
was monitored by western blot analysis (Figure 2F). Microscopy
examination at 48 hr post-infection revealed no significant differ-
ence in parasite size in cells not expressing the plasmids (Fig-
ure S2B). However, cells expressing the CA plasmid harbored
significantly smaller hepatic schizonts, compared to controls2540 Cell Reports 16, 2539–2545, September 6, 2016(CA, 132.9 ± 83 mm2; T172A, 207.2 ± 119 mm2; and empty,
198.4 ± 92 mm2, p < 0.01; Figures 2G and 2H), implying that
increased host AMPK activity decreases P. berghei hepatic
growth.
AMPK Agonists Restrict Plasmodium Hepatic Infection
In Vitro
The impact of host AMPK activation during P. berghei infec-
tion was further characterized using a pharmacological
approach.We exposed infected cells to known AMPK-activating
compounds (salicylate, metformin, 2-deoxy-D-glucose, and
A769662) (Hardie, 2014) (Table S1) and analyzed infection via
luminescence and immunofluorescence assays in Huh7 cells
(Figure S3). A dose-dependent reduction of total parasite load
was observed for all tested compounds, with calculated half
maximal effective concentration (EC50) values ranging from
200 mM to 1 mM (Figure S3A; Table S1), which are within or
below the range described for other mammalian cell systems.
Microscopy analysis revealed that AMPK-activating compounds
led primarily to a significant decrease in schizont size, but not
parasite numbers (Figures S3B and S3C).
To dissect the effect of host AMPK activation on parasite
infection, we focused on salicylate, known to bind the AMPKb1
subunit promoting AMPKa T172 phosphorylation (Hawley et al.,
2012) (Figures 3A and 3B). The data show a similar negative ef-
fect on parasite development in Huh7 cells (40 ± 20.3 mm2
versus 177 ± 101.5 mm2, p < 0.0001; Figure 3C) and mouse pri-
mary hepatocytes infected with P. berghei (94.36 ± 36 mm2
versus 272.2 ± 209 mm2, p < 0.0001; Figure 3D), Hepa1-6 cells
infected with P. yoelii (71 ± 42 mm2 versus 180.9 ± 106 mm2,
p < 0.0001; Figure 3E), and human primary hepatocytes
derived from different donors infected with P. falciparum (38 ±
23.9 mm2 versus 84 ± 40.9 mm2, p < 0.0001; Figure 3F). Thus,
treatment with salicylate during hepatic infection leads to a
reduction in parasite size, regardless of host cell or Plasmodium
species.
To determine the time-course kinetics during which activated
AMPK restricts parasite development, we exposed cells to
salicylate at different time intervals post-infection. We observed








Figure 2. Modulation of Host AMPK Activity
Alters P. berghei Development
(A) Timeline of RNAi knockdown (KD) and infec-
tion.
(B) pAMPKaT172 and pACCS79 status in lysates of
Huh7 cells 48 hr after AMPK a1 and a2 KD.
Representative blot of three independent experi-
ments (KD efficiency, mean±SEM, 64.3% ±
10.3%).
(C and D) Quantification of parasite size in
AMPKa1/a2-depleted Huh7 cells (C) or
AMPKa1/a2/ MEFs (D), assessed by micro-
scopy at 48 hr post-infection. Parasite size is the
area defined by staining with the parasite mem-
brane marker PbUIS4, as shown in the represen-
tative images. Nuclei were stained with Hoechst.
More than 100 parasites were imaged and
analyzed for each of the three independent ex-
periments. ctrl, control; wild type (WT). Scale bars,
20 mm. ****p < 0.0001. The outliers in the boxplots
represent 5% of data points.
(E) Timeline of transfection with AMPKa1-carrying
plasmids and infection.
(F) Representative western blot of pAMPKaT172
and pACCS79 in lysates of Huh7 cells transfected
with the truncated AMPKa1, constitutively active
(CA), and mutated AMPKa1 (T172A) plasmids (see
schematic of AMPKa1 domains and GST-tagged
constructs in Figure S2A). GST was probed to
detect transgenes.
(G and H) Representative images (G) and quanti-
fication (H) of parasite size in cells expressing
AMPKa1-CA, AMPKa1-T172A, or GST only
(empty plasmid) in transfected or untransfected
cells (ctrl). Transfected cells were identified with
anti-GST antibodies, and parasites were detected
with anti-PbUIS4. Nuclei were stained with
Hoechst. Parasite size distribution in GST-nega-
tive cells is shown in Figure S2B. A representative
of three independent experiments is shown (30–60
parasites examined per condition). The outliers in
the boxplot represent 10% of data points. Scale
bars, 20 mm. **p < 0.01; ns, non-significant.during the first 24 hr (Figure 3G). We then allowed P. berghei to
fully mature in vitro under salicylate treatment into the final end-
stage of hepatic development, when merosomes containing
fully mature merozoites are released from the substratum
(66 hr; Sturm et al., 2006). First, we visualized the live
GFP signal of detached merosomes from GFP-expressing
P. berghei-infected cells at 66 hr and observed a reduction in
merosome size (239 ± 135 mm2 versus 411 ± 311 mm2, p <
0.01; Figures 3H and S4A) and numbers (0.9 ± 0.9 per field
versus 9 ± 4.5 per field, p < 0.0001; Figure S4B). Then, we
examined luminescence levels from luciferase-expressing de-
tached merosomes and observed an 80% reduction in total
load up to 74 hr (p < 0.0001; Figure S4C), indicating that the
decrease was not simply a delay in merosome release. Addi-
tionally, we performed immunofluorescence analysis with the
merozoite surface marker (MSP1), essential for merozoite matu-
ration, and observed that salicylate-treated cells contained
smaller MSP1-positive schizonts (Figure S4D). The datademonstrate that AMPK agonists cause a reduction in parasite
development during schizogony, with decreased release of
merosomes, suggesting that the total number of merozoites
reaching the blood to infect erythrocytes would be lower.
AMPK Activation Reduces P. berghei Infection in Mice
Next, we asked whether our in vitro findings were relevant to an
in vivo setting. First, we injected mice with salicylate to boost
AMPK activity (Hawley et al., 2012) and confirmed increased
AMPKa phosphorylation in mouse livers (Figures 4A and 4B).
Then, mice were infected by intradermal injection of sporozoites,
mimicking a natural mosquito bite. Parasite development under
salicylate treatment mirrored the effects observed in vitro, with a
significant reduction in size compared to control mice at 42 hr of
infection (150.2 ± 110 mm2 versus 501.9 ± 35 mm2, p < 0.0001;
Figures 4C and 4D). Next, we used flow cytometry to monitor
the number of infected erythrocytes 72 hr after infection and





Figure 3. Pharmacological Activation of
AMPK Reduces Plasmodium Infection
(A) Timeline of infection and microscopy analysis
upon treatment with salicylate (sal) or vehicle (ctrl,
water) at 2 hr post-infection. Dose-dependent ef-
fects of salicylate and other AMPK agonists (met-
formin, 2-deoxy-D-glucose, and A769662) are
shown in Figure S3.
(B) Representative western blot of pAMPKaT172
and pACCS79 in lysates of non-infected Huh7 cells
treated with salicylate (2.5 mM) for 24 hr.
(C–F) Effect of salicylate treatment in Huh7 (C) or
mouse primary hepatocytes (D) infected with
P. berghei (Pb), Hepa1–6 cells infected with
P. yoelii (Py) (E), and human primary hepatocytes
infected with P. falciparum (Pf) (F). Pb and Py,
2.5 mM; Pf, 2 mM salicylate. Boxplots of parasite
size distribution and illustrative images of three to
four independent experiments are shown. Parasite
size was determined based on the UIS4 or HSP70
signal after immunofluorescence assays. Nuclei
were stained with Hoechst. Pb and Py scale bars,
20 mm; Pf scale bar, 10 mm. ****p < 0.0001.
(G) Time-course analysis of salicylate treatment
(2.5 mM) starting at 6, 12, and 24 hr after infection
of Huh7 cells with luciferase-expressing P. berghei
parasites. Relative luminescence values (RLU)
were measured at 48 hr. The bars are means ±
SEM normalized to corresponding control, from
three independent experiments. Cell viability (right
y axis), measured by Alamar blue, is represented
by the blue data points above each bar. **p < 0.01;
***p < 0.001.
(H) Size distribution scatterplot of detached mer-
osomes from GFP-expressing P. berghei-infected
HepG2 cells treated with salicylate (2.5mM) from 2
to 66 hr. Data plotted is mean±SD, vehicle
411±311mm2, salicylate 239±135mm2. Data ob-
tained from 3 independent experiments. Live GFP
images of representative merosomes are shown.
Bright-field images and quantification of detached
merosome numbers are in Figures S4A and S4B.
Data were obtained from three independent ex-
periments. See Figure S4C for merosome analysis
at later time points (66–74 hr) and Figure S4D for
MSP1 staining at 66 hr. Scale bars, 50 mm. **p <
0.01.three doses of salicylate (p < 0.01; Figure 4E). A single dose was
not sufficient to cause a significant reduction in parasitemia (data
not shown).
As an alternative, we used a dietary restriction protocol, a
method that activates AMPK via alterations in AMP/ATP ratios
(Hardie, 2014). We restricted mice food intake by 30%–40%
for 2–3 weeks prior and during liver-stage infection, leading to
the expected body weight loss (Figures 4F, S5A, and S5B)
and efficiently increased liver AMPK activation (Figures 4G
and S5C). Physiological activation of AMPK resulted in a signifi-2542 Cell Reports 16, 2539–2545, September 6, 2016cant reduction of hepatic schizont size
(252.8 ± 34 mm2 versus 399.6 ± 29 mm2,
p < 0.0001; Figures 4H and 4I) and
pre-patent blood stage infection (66%reduction, p < 0.01; Figure 4J), similar to salicylate treatment.
Altogether, these results show that induction of host AMPK
activity affects the ability of the host cell to support parasite
growth in the liver, thus reducing the subsequent malaria burden.
DISCUSSION
The present study identifies host cell AMPK signaling as rele-
vant to malaria liver-stage infection. We demonstrate that, while








Figure 4. In Vivo Activation of AMPK Reduces Liver-Stage Infection
(A–E) C57BL/6 mice treated with salicylate (sal, 300 mg/kg) or vehicle (ctrl, NaCl 0.9%).
(F–J) C57BL/6 mice fed ad libitum (AL) or a dietary restriction (DR) regimen. Food intake and body weight changes are shown in Figures S5A and S5B.
(A and F) Schedule of the treatments/diets, infections, and sample collection.
(B and G)Western blot of pAMPKaT172 status in liver homogenates from non-infectedmice 1 hr after injection of salicylate or vehicle (B) and non-infected mice on
AL and DR diets (G). Quantification of pAMPKaT172 for AL and DR mice is given in Figure S5C. Numbers 1–3 represent individual mice.
(C and H) Confocal representative images from infected livers. Scale bars, 20 mm.
(D and I) Microscopy quantification of P. berghei size (area) in liver sections at 42 hr after infection. The parasite area was obtained after immunostaining with anti-
PbUIS4 antibodies, as in Figures 2 and 3. Data were pooled from three mice per group (>100 parasites per mouse). The outliers in the boxplots represent 5% of
data points.****p < 0.0001.
(E and J) Percentage of infected erythrocytes (parasitemia) measured by flow cytometry (R8 mice per group) at 72 hr after infection. Data plotted is mean±SEM
(3102), vehicle 1.33±0.28, salicylate 0.56±0.08, AL 1.03±0.19, DR 0.34±0.13. Data were pooled from two independent experiments. **p < 0.01.infection, its activation has a negative impact on parasite
growth. The results provide further insights into host hepatocyte
signaling and reveal an emerging pattern where the host cell
has increased Akt activity, decreased p53 (Kaushansky et al.,
2013), and, as shown here, decreased AMPK activity. One
advantage of such alterations in the infected cell is a metabolic
state that supports rapid proliferation, known as the Warburg
effect, a strategy that appears to be used by the parasite itselfduring schizogony, at least during erythrocytic stages (Salcedo-
Sora et al., 2014).
Suppression of AMPK during hepatocyte infection may
create a permissive environment serving multiple purposes,
for example, through the inhibition of host autophagy (Kim
et al., 2011), which may lead to parasite elimination. Alterna-
tively, inhibition of AMPK and downstream targets (e.g., ACC)
may help maintain the host cell biosynthetic capacity to sustainCell Reports 16, 2539–2545, September 6, 2016 2543
massive parasite replication. Indeed, Plasmodium is auxotro-
phic for certain metabolites, such as cholesterol (Labaied
et al., 2011) and lipoic acid (Deschermeier et al., 2012), and
scavenges host-derived phosphatidylcholine from hepatocytes
(Itoe et al., 2014). A halt in cholesterol and fatty acid synthesis
and breakdown, when AMPK is chronically activated, could
have a negative impact on parasite growth. Such a mechanism
has been described for HCV and Rift Valley Fever virus infec-
tions (Mankouri et al., 2010; Moser et al., 2012).
How are the levels of active AMPK lowered and maintained
low during infection? This process can be a coping response
from the host cell to the invading pathogen or a process
prompted by the parasite. Plasmodium may actively promote
inactivation of AMPK via its own effector molecules or indirectly
through modulation of other host cell signaling pathways, lead-
ing to decreased AMPK function. As a member of the phylum
Apicomplexa, Plasmodium sporozoites possess specialized
organelles (micronemes and rhoptries) that secrete and inject
molecules into host cells during invasion (Kemp et al., 2013).
Furthermore, Plasmodium is also known to transport proteins
beyond the parasite confines during intracellular hepatic growth
(Kalanon et al., 2016; Singh et al., 2007). Alternatively, the
sporozoite, known to traverse several hepatocytes before final
invasion (Mota et al., 2001; Risco-Castillo et al., 2015), may
establish infection in a cell with pre-existing low AMPK
activity. Whether malaria sporozoites select to home in a cell
with suppressed AMPK or modulate host AMPK activity via
secretion/transportation of parasite-derived effector molecules
remains to be determined.
AMPK activation via small-molecule treatment has been
extensively studied, as clinically available drugs (salicylate
and metformin) are widely used for treating conditions such
as inflammation and diabetes, and are now being evaluated
for their anti-tumorigenic properties (Hardie, 2014). Our results
demonstrate that salicylate treatment of hepatocytes infected
with rodent and human malaria parasites results in reduced
parasite replication, which was also shown in vivo with
P. berghei and is consistent with the effect of overexpressing
a constitutively active AMPK in vitro. One caveat of using small
molecules to induce AMPK activity is the possible lack of
specificity. Salicylate, for example, at high doses has been
described to uncouple mitochondria respiration and inhibit
necrosis factor kB (NF-kB) signaling (Hawley et al., 2012; Stein-
berg et al., 2013). Thus, we cannot exclude that our observa-
tions with salicylate on parasite replication are fully AMPK
dependent. Future experiments using liver-specific genetic
mouse models of AMPK are necessary to assess the specificity
of salicylate treatment or food restriction effect on liver infec-
tion. Furthermore, it would be worthwhile to investigate the
impact of AMPK during Plasmodium infection of erythrocytes,
where AMPK is important to regulate cell survival (Fo¨ller
et al., 2009).
High energetic demands and auxotrophy by intracellular path-
ogens present a targetable approach to limit their growth. Drugs
typically target pathogen-specific molecules, but due to the risk
of selecting and spreading drug-resistant parasites, targeting of
host molecules or pathways critical for successful pathogen
development is an enticing strategy toward disease control.2544 Cell Reports 16, 2539–2545, September 6, 2016Host-based interventions have already been proposed against
several pathogens, including hepatic and erythrocytic Plasmo-
dium stages. For example, host p53 and Bcl-2 (Douglass et al.,
2015), heme oxygenase 1 (Pena et al., 2012), erythrocyte G pro-
tein (Murphy et al., 2006), and MEK kinases (Sicard et al., 2011)
have been suggested as potential targets. This concept is partic-
ularly valuable in the context of co-infections where multiple
diseases could be tackled at once. The results presented
here reveal the host AMPK as a druggable target with the
potential to be further explored for antimalarial chemoprophy-
laxis and/or combination therapies.
EXPERIMENTAL PROCEDURES
Cells, Transfections, and Infections
Cells were infected by adding freshly dissected P. berghei, P. yoelii, or
P. falciparum sporozoites and analyzed by immunofluorescence assay or lumi-
nescence assay for luciferase-expressing parasites. For AMPKa knockdown,
siPOOLs antisense oligonucleotides directed against prkaa1 and prkaa2 were
used (siTOOLs Biotech). For AMPKa1 overexpression, cells were transiently
transfected with pEBG-AMPKa1 plasmid (27632, Addgene) prior to infection.
Mice, Diets, and Treatments
Male C57BL/6 mice were grouped based on body weight, housed four to five
per cage, and allowed free access to water and food, except for mice on
dietary restriction, which were given daily 60%–70% of the food consumed
by the control group. Salicylate treatment was performed by intraperitoneal in-
jection. Mice infections were performed by intravenous (5 3 104 spz per
mouse) or intradermal (5 3 103 spz per mouse) injections and analyzed by
microscopy on extracted livers or by flow cytometry, respectively. All experi-
ments in animals were approved by the animal ethics committee at Instituto
deMedicina Molecular, Lisboa (Portugal) and performed according to national
and European regulations.
Statistical Analysis
Statistics were determined with a Student’s t or Mann-Whitney U test for com-
parisons between two conditions and a one-way ANOVA for comparisons
involving three or more conditions. Statistical significance was considered
for p values below 0.05. The outliers in the boxplots represent 5%–10% of
data points. Values in bar graphs are means ± SEM, and data mentioned in
the text are means ± SD.
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